Pharma BD Deal Intelligence
Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases. Travere will bolster its rare kidney disease platform by licensing…
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside. Shares fell as much as 6% on Tuesday following announcement of the…
Why is Travere Therapeutics stock rallying today? Travere stock rose 3.1% in morning trading as the company secured global rights to civorebrutinib, a…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
On June 2, 2026, Travere Therapeutics entered an exclusive license and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), an investigational oral covalent reversible BTK inhibitor for immune-mediated rare kidney diseases. Travere obtains rights in all countries outside Greater China and certain East/Southeast Asian markets (which Everest retains). Travere pays $112.5 million upfront and Everest is eligible for up to approximately $1.03 billion in clinical, regulatory and commercial milestones across up to five indications, plus tiered high-single-digit to double-digit royalties — total potential value of roughly $1.14 billion. A ten-year mutual non-compete on competing BTK products applies, subject to change-of-control exceptions. The asset extends Travere's rare kidney disease platform alongside Filspari.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Travere Therapeutics, Inc. / Everest Medicines Limited (this deal) | 2026 | $1.1B | 72 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · Immunology deals